KRAS and neoplasm: Notably, MKC8866 inhibited tumor growth in MYC-overexpressing BCa patient derived xenograft (PDX) models and enhanced the efficacy of docetaxel [83]; in addition, in pancreatic cancer, MKC8866 treatment helped overcome resistance to KRAS inhibitors leading to rapid tumor regression [84], indicating its potential therapeutic promise in multiple cancer types.